Lipitor patent reissue rejected, for now

Share this article:
Pfizer will look to re-submit corrections to its US Lipitor patent after the US Patent and Trademark Office rebuffed an initial attempt. Reissuing a corrected patent, as Pfizer is seeking to do, would help the company retain US marketing exclusivity on atorvastatin until 2011.

Last year the patent term on the anti-cholesterol med was shortened by a year, from June 2011 to March 2010, when a federal appeals court deemed one Lipitor patent invalid, reversing a lower court's decision. Generic manufacturer Ranbaxy had challenged the patent.

At the time, Pfizer said that the decision “turned on a technical defect” and that it planned to apply to the PTO to correct it.

As Pfizer spokesman Bryant Haskins told The Wall Street Journal , “An initial rejection is not uncommon in reissue application proceedings.” He went on to say that once the company receives a letter from the PTO explaining its decision, it will review and respond appropriately to address any issues raised.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions